Labcorp Holdings (NYSE:LH) launched the first FDA cleared blood test to aid in the initial assessment of Alzheimer’s disease, the Elecsys pTau-181 test, with nationwide availability. The company also ...

Detailed price information for Laboratory Corp of America Holdings (LH-N) from The Globe and Mail including charting and trades.

Labcorp Holdings Inc. (NYSE:LH) Q4 2025 Earnings Call Transcript February 17, 2026 Labcorp Holdings Inc. misses on earnings expectations. Reported EPS is $1.98 EPS, expectations were $3.95. Operator: ...

Labcorp (NYSE:LH) executives said the company delivered what CEO Adam Schechter called a “very strong year” in 2025, citing ...

Labcorp Holdings Inc. , a global leader of innovative and comprehensive laboratory services, today announced results for the fourth quarter and full year ended December 31, 2025, and provided 2026 ...

Competitive dynamics loom large. Quest Diagnostics recently delivered 7.1% year-over-year revenue growth, beating estimates by 1.9%, with shares rallying 9.4% following results. That strong showing ...

In February 2026, Labcorp announced nationwide availability of the Elecsys pTau-181 blood test, the first FDA-cleared primary-care tool to aid in ruling out Alzheimer’s disease by identifying ...

The company plans to begin using the instrument in its Burlington, North Carolina, lab in the first quarter of the year and ...

Labcorp is now offering Roche Diagnostics' recently FDA-cleared Alzheimer’s disease blood test to help primary care doctors rule out the disease in people 55 and older with symptoms of cognitive ...

Elecsys® pTau-181 test helps clinicians rule out Alzheimer's disease by identifying patients unlikely to have amyloid pathology Now available nationwide in primary ...

BURLINGTON, N.C., Feb. 11, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the nationwide availability of the Elecsys® ...